Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.65 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.65 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006814 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1005572 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1006544 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007485 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1008153 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1008879 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1006947 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1006839 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007208 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1007446 | 1.00 | LCK (0.65) | LCKPPARDZDHHC20ZDHHC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | claimed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| EP-3292120-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | claimed |
| US-9845322-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-12-19 | — | — | US | claimed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | claimed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| EP-4219767-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| CN-109328237-B | Inhibitors of PAPD5 and PAPD7 for the treatment of hepatitis b infection | 豪夫迈·罗氏有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2021-12-07 | — | — | US | disclosed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-20190194768-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-20060058338-A1 | for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF- alpha release, particularly obstructive or inflammatory airways disease | DENHOLM ALASTAIR | 2006-03-16 | — | — | US | disclosed |
| EP-1575950-A1 | [1,7]NAPHTHYRIDINES AS PDE4 INHIBITORS | Novartis AG (CH) | 2005-09-21 | — | — | EP | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| WO-2004055013-A1 | [1,7]NAPHTHYRIDINES AS PDE4 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058338-A1 | for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF- alpha release, particularly obstructive or inflammatory airways disease | PDE4A, PDE4B, PDE3A | LCK 3758/4885PPARD 2928/4885ZDHHC20 3131/4885 |
| US-20190194768-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HAVCR2, BRD7, ZC3HAV1 | LCK 4595/4885PPARD 1580/4885ZDHHC20 394/4885 |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | TPMT, DPYD, HAVCR2 | LCK 1045/4885PPARD 1233/4885ZDHHC20 932/4885 |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HAVCR2, BRD7, ZC3HAV1 | LCK 4595/4885PPARD 1580/4885ZDHHC20 394/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | LCK 2085/4885PPARD 1860/4885ZDHHC20 3495/4885 |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HAVCR2, BRD7, BAZ2B | LCK 4593/4885PPARD 1528/4885ZDHHC20 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.